65,437 trials
Total Knee Arthroplasty
Primary: Cumulative 24 Hour Oral Morphine Equivalent Consumption — 111.8; 118; 153 mg
Lymphoma
Primary: Number of Subjects With Dose-limiting Toxicities — 0 Participants
Carcinoma, Hepatocellular
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity as Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse…
Primary Haemophagocytic Lymphohistiocytosis
Primary: Overall Response Rate (ORR) Second Line — 63.0 percentage of participants — p=0.0134
Irritable Bowel Syndrome · Placebo Effect · Placebos
Primary: Change in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS) From Baseline to Six Weeks. — 74.6; 94.6; 56.4; 90.8 score on a scale
Advanced Cancers
Primary: Dyspnea Numeric Rating Scale — -2.0; -1.7; -2.3; -2.5 score on a scale
Cataract
Primary: Mean Percent Cell Change (Preservation of Endothelium) — -10.05; -10.13 percent cell change
Multiple Sclerosis · Internuclear Ophthalmoplegia · Fatigue
Primary: Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity. — 1.914; 1.937; 1.805; 1.898 ratio — p=0.842672
Spinal Cord Injuries
Primary: Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Resistance — -0.692; 0.23 correlation coefficient — p=0.006
Diabetes · Heart Failure
Primary: Health-Related Quality of Life (HRQoL) — 37; 37 score on a scale
Wound; Hip
Primary: Time to Close, Minutes — 18.0; 21.0 minutes
Heart Failure · Diabetes
Primary: Health-Related Quality of Life (HRQoL) — 56; 53 score on a scale
Infections, Bacterial
Primary: Part 1- Period 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Time of the Last Quantifiable Concentration (AUC[0-t]) After Single Dose…
Conjunctivitis, Allergic
Primary: Ocular Itching — 1.71; 1.34; 2.11; 2.06 score on a scale
Dry Eye Syndrome
Primary: Mean Ocular Surface Disease Index (OSDI) Total Score — 35.0; 40.3; 36.9 score on a scale